Translation of evidence-based Assistive Technologies into stroke rehabilitation: users’ perceptions of the barriers and opportunities by unknown
Hughes et al. BMC Health Services Research 2014, 14:124
http://www.biomedcentral.com/1472-6963/14/124RESEARCH ARTICLE Open AccessTranslation of evidence-based Assistive
Technologies into stroke rehabilitation: users’
perceptions of the barriers and opportunities
Ann-Marie Hughes1,2*†, Jane Helena Burridge1†, Sara Holtum Demain1, Caroline Ellis-Hill3†, Claire Meagher1†,
Lisa Tedesco-Triccas1†, Ruth Turk1† and Ian Swain4,5†Abstract
Background: Assistive Technologies (ATs), defined as “electrical or mechanical devices designed to help people
recover movement”, demonstrate clinical benefits in upper limb stroke rehabilitation; however translation into
clinical practice is poor. Uptake is dependent on a complex relationship between all stakeholders. Our aim was to
understand patients’, carers’ (P&Cs) and healthcare professionals’ (HCPs) experience and views of upper limb
rehabilitation and ATs, to identify barriers and opportunities critical to the effective translation of ATs into clinical
practice. This work was conducted in the UK, which has a state funded healthcare system, but the findings have
relevance to all healthcare systems.
Methods: Two structurally comparable questionnaires, one for P&Cs and one for HCPs, were designed, piloted and
completed anonymously. Wide distribution of the questionnaires provided data from HCPs with experience of
stroke rehabilitation and P&Cs who had experience of stroke. Questionnaires were designed based on themes
identified from four focus groups held with HCPs and P&Cs and piloted with a sample of HCPs (N = 24) and P&Cs
(N = 8). Eight of whom (four HCPs and four P&Cs) had been involved in the development.
Results: 292 HCPs and 123 P&Cs questionnaires were analysed. 120 (41%) of HCP and 79 (64%) of P&C respondents
had never used ATs. Most views were common to both groups, citing lack of information and access to ATs as the
main reasons for not using them. Both HCPs (N = 53 [34%]) and P&C (N = 21 [47%]) cited Functional Electrical
Stimulation (FES) as the most frequently used AT. Research evidence was rated by HCPs as the most important
factor in the design of an ideal technology, yet ATs they used or prescribed were not supported by research
evidence. P&Cs rated ease of set-up and comfort more highly.
Conclusion: Key barriers to translation of ATs into clinical practice are lack of knowledge, education, awareness and
access. Perceptions about arm rehabilitation post-stroke are similar between HCPs and P&Cs. Based on our findings,
improvements in AT design, pragmatic clinical evaluation, better knowledge and awareness and improvement in
provision of services will contribute to better and cost-effective upper limb stroke rehabilitation.
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Stroke is a leading cause of disability world-wide [1]. Be-
cause it is an age related disease, incidence is likely to
rise. Prevalence is also likely to rise due to better survival
rates and long-term care. In the UK alone over 110,000
people have a stroke annually and over 300,000 people
are living with disability as a result of a stroke. The com-
bined societal cost of treatment and lost productivity is
£8.9 billion a year, with treatment costs accounting for
approximately 5% of total UK National Health Service
(NHS) costs [2].
Disability and dependence associated with reduced
upper limb function following stroke impacts on pa-
tients’ and carers’ (P&Cs’) quality of life [3] and national
economies [4,5]. Approximately 85% of stroke patients
have upper limb impairments at stroke onset. The major-
ity of these will not regain useful function [6-8], particu-
larly affecting the 75% of younger individuals who want to
return to work [9]. Consequently evaluation of the effect-
iveness of rehabilitation interventions after the acute phase
of stroke is one of the National Stroke Strategy’s top ten
priorities for stroke services research, and identification of
best practice in the rehabilitation of the upper limb in pa-
tients with stroke with respect to timing, content and dos-
age is the highest prioritised research topic [10]. Demand
for more cost-effective treatment is leading to changes in
practice that are likely to involve Assistive Technologies
(ATs) in addition to conventional occupational therapy
and physiotherapy. National strategies and frameworks
continue to emphasise the need for informed decision
making in healthcare that are research led and evidence-
based, yet the UK, Australian and US National Clinical
Guidelines for Stroke indicate that there is limited re-
search to assess efficacy of ATs, either individually or in
combination [8,11,12].
It has been demonstrated that the main predictor of
success in physical therapy is intensity [13] and that key
components are optimum content, optimum delivery and
optimum structure [5]. ATs may provide increased inten-
sity without a corresponding increase in clinical contact
time, motivating and relevant activities (either functional
or impairment based), and may be performed outside the
hospital [14]. They therefore have the potential to improve
cost effectiveness of upper limb stroke rehabilitation.
Rehabilitation
An important aim of rehabilitation is to promote neuro-
plasticity within the central nervous system and ameliorate
secondary effects of stroke such as muscle weakness and
reduced range of motion. Neurological re-organisation or
learning occurs in response to experience gained through
afferent inputs. Studies have demonstrated that functions,
previously the responsibility of damaged areas of the cor-
tex, may be taken over by adjacent areas or by areas in thecontralateral hemisphere [15]. However, the disability itself
can be a significant barrier to obtaining the afferent feed-
back necessary to promote learning. The aim of ATs is
therefore promotion of these processes, enabling more
sustained and engaging practice i.e. supporting behavioural
training. There is growing evidence that relearning of func-
tion is encouraged by appropriate functional practice of
meaningful tasks aimed at acquiring a practical skill, rather
than simple repetition of a movement [16]. In the future,
ATs are likely to be used by patients at home, used either
independently or supported by the multidisciplinary team,
which will change the focus of responsibility for reha-
bilitation and may result in the long term continuation of
regular exercise and functional training.
Assistive Technologies (ATs)
The definition of Assistive Technologies (ATs) used in this
study was electrical or mechanical devices designed to help
people recover movement of their upper limb. ATs are in-
creasingly used to augment conventional physiotherapy
and occupational therapy. Descriptions used to explain the
ATs mentioned in the questionnaires (Additional files 1
and 2) are as follows: Virtual Reality (VR), computer games
that you play by moving your arm and hand. Sometimes
you see an image of your arm and the way it is moving
on the computer screen; Dynamic splints: e.g. Saeboflex -
devices that you wear. They may have strapping or springs
to help you open your hand to pick up objects. Biofeed-
back: where the device tells you immediately about your
arm movement; Robots: devices that support your arm
and/or hand and help you to move while you either play
computer games or practise manual tasks; Constraint In-
duced Movement Therapy (CIMT): where you wear a
glove on your good hand for about six hours a day for a
few weeks; and Functional Electrical Stimulation (FES):
sticky pads or a device over your skin which transmits
small electrical impulses.
Evidence is growing for the use of ATs to reduce
impairments and in some cases improve function.
Systematic reviews support the use of robotics [17], FES
[18], CIMT [19], and VR [20] and in combination
[21-26]. Although studies of the combined treatment
have demonstrated benefits, in general, they have been
inadequately powered. Despite the inconclusive clinical
evidence for ATs, rapid advances continue to be made in
the technology. It is therefore critical that design is
informed not only by trials of clinical effectiveness, most
of which have been experimental rather than pragmatic,
but also by what is acceptable to users.
Design of clinically useful ATs requires consideration
of multiple and sometimes competing factors such as
effectiveness, cost, ease of use and aesthetics and, there-
fore, requires knowledge of users’ priorities. There has
been speculation over possible reasons for the lack of
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empirical research.
Our aim was to understand P&Cs’ and healthcare pro-
fessionals’ (HCPs’) experiences and perceptions of ATs
and upper limb stroke rehabilitation, to identify barriers
and opportunities critical to the effective translation of
ATs into clinical practice. To achieve our aim we sought
the views of P&Cs and HCPs via questionnaires. The de-
sign of the questionnaires was informed by output from
an interactive exhibition and focus groups. Two hundred
and four people (HCP 49%, P&C 51%) attended the
interactive exhibition over 3 days with 12 different com-
panies displaying 27 different ATs. Awareness was raised
about the research study, and people were invited to
leave contact details if they wanted to have further infor-
mation about the study. The exhibition thus provided an
opportunity for people to reflect on their own experi-
ences and needs in the context of a range of ATs and
identified a group of people with an interest in this
area. This group was sampled to form the four focus
groups of HCPs and P&Cs who had and had not used
ATs. Full details of the focus group methodology, re-
sults and conclusions are available [27].Method
HCP and P&C questionnaire design and development,
piloting, dissemination and data analysis plan is described.
The questionnaires (Additional files 1 and 2) were co-de-
signed and piloted, using iterative testing and revising
throughout the process.Participants
24 HCPs and 8 P&Cs were recruited to contribute to the
design and piloting of the questionnaires. All were repre-
sentative of the questionnaire target groups. Criteria for
recruitment were, for the HCP group, at least one of: a)
member of the project steering committee and/or resear-
cher on the project; b) attendee at the exhibition; c) HCP
working in stroke rehabilitation. All P&Cs were either
stroke survivors or carers of a stroke survivor, with or
without experience of ATs, who had: a) had attended of
the exhibition; or b) been a member of one of the focus
groups; or c) was a member of a local stroke group.
Questionnaire respondents were self-selected. Responses
to questions 1 and 2 in the HCP questionnaire ensured
that respondents satisfied the single criterion: were
either a nurse, occupational therapist, physiotherapist,
doctor or other HCP who had experience of upper limb
stroke rehabilitation. Response to question 2 in the
P&C questionnaire ensured that respondents satisfied
the criteria: were either a person who has had a stroke
or a carer, such as a friend, or relative of someone who
has had a stroke.Questionnaire design and development
Questions were identified from the following sources:
focus group data; feedback from the exhibition and pub-
lished systematic reviews of the AT literature [17,19,28].
Structure and design of the questionnaires was informed
by published literature on questionnaire design [29-31].
The authors reached a consensus on content and design.
Revisions to the first drafts of the questionnaires were
then made following consultation with the project steer-
ing committee (N = 9) comprising national and inter-
national experts in: clinical services; clinical, engineering
and psychology AT research; health economics as well
as patient group representatives (Stroke Association,
Different Strokes), and a stroke survivor. This ensured
that questions on all aspects of ATs were included in the
questionnaires and that the questions were generated
from the perspective of the target audience. Initial face
and content validity were established through consult-
ation with experts within the steering committee.
The design of the two questionnaires (Additional files
1 and 2) was kept as similar as possible so that compari-
sons could be made between the two groups of respon-
dents. Within the questionnaires, open questions were
avoided where possible to allow direct coding. Closed
questions included: Yes/No answers, Likert scales and
multiple-choice. Multiple-choice questions were used to
identify which ATs were used. Choices had been identi-
fied from focus group data and were: FES, VR, CIMT;
Dynamic Splints; biofeedback; rehabilitation robots and
an option to identify ‘any other’ that was not listed.
Questionnaire piloting
The questionnaires were piloted with four HCPs and
four P&Cs who had attended the focus groups or the
exhibition and 20 HCPs, researchers and patient repre-
sentatives (recruited from the steering committee and
from HCPs working in stroke rehabilitation) and four
P&C (from a local stroke club) who had not attended
and had not had input into the design. Including naïve
participants reduced bias towards the views of partici-
pants who had contributed to the initial development.
All participants were asked for their comments on the
scope of the topics and whether there were missing areas
of interest. Based on participant responses, amendments
were made to the wording of some questions and the
omission of two questions. Following revision, two
further samples of P&Cs and HCPs who had attended
the focus groups were asked to complete the ques-
tionnaires independently, after which they took part
in a telephone discussion with one of the researchers
to check that all questions conveyed the same meaning to
each participant and were not ambiguous. Participants
were also asked to comment on the style and ease of
completion etc.
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the questionnaires were developed from the paper ver-
sions. Question order was the same in both versions to
reduce risk of bias by primacy effects. The electronic
versions of the questionnaires were then piloted with
representatives of each target population who had not
attended the focus groups (N = 2 HCPs N = 2 P&Cs).
During development and piloting, user feedback identi-
fied issues with suitability and utility within the respondent
groups and, in response, modifications were made to
content, style and language.
Questionnaire dissemination
The HCP questionnaires were advertised widely through
HCP special interest groups, at professional conferences,
via professional bodies, through the project website
hosted by the UK National Institute of Health Research
and through personal contacts. Preliminary questions
about profession and experience provided demographic
participant data and were used to screen respondents to
ensure they satisfied the selection criteria. However, as
the questionnaires were predominantly online, whilst we
targeted the relevant groups, we were unable to control
who would respond or the veracity of their responses. For
the P&C questionnaires a pre-awareness campaign was
launched via UK charities: Different Strokes (Newsletter)
[32] and the websites of The Stroke Association and
Different Strokes, and then also distributed via voluntary
organisations representing P&Cs. Preliminary questions
provided demographic participant data and ensured that
respondents satisfied the selection criteria. To ensure
maximum inclusivity, the questionnaires could also be
completed by telephone, online via a hyperlink on an
email, and paper based via post.
Ethical approval and consent
Ethical approval was granted from the Isle of Wight,
Portsmouth and South East Hampshire Research Ethics
Committee (09/H0501/71). In accordance with ethical
approval, consent to participate was assumed following
completion and submission of the questionnaires. Re-
sponses were anonymous.
Analysis
Returned questionnaires were included in the analysis if
questions 1–3 had been completed. Nominal, discrete
and ordinal data from the online surveys populated an
Excel spreadsheet. Double data entry was used to input
the results from the paper-based copies. The resulting
data were then imported into SPSS (version 18) for stat-
istical analysis. Categorical data (e.g. gender, profession
and carer or patient) and responses to “have you used
any of the following ATs?” were described with counts
and percentages. Factors affecting ‘ideal design’ wereranked using an ordinal scale. Descriptive, rather than
inferential data analysis was used to summarise data.
Sub-group analysis, by for example profession or expe-
rience, was not performed due to the limitations of
sample size.
Results
A total of 419 questionnaires were returned, 296 (71%)
from HCPs and 123 (29%) from P&Cs. Of the 296 HCP
returns, 26 of the 44 (59%) were posted questionnaires
and 270 of the 635 (43%) were online accessed question-
naires. Of the 123 P&C returns, 54 (44%) were postal
and, although 597 people opened the online version,
only 59 (10%) were completed beyond question 3 and
therefore included in the analysis. Ten P&C question-
naires were completed face-to-face. Data from all modes
of response were combined. Four people who responded
to the HCP questionnaire were not included in the ana-
lysis as they did not satisfy the selection criteria being ei-
ther Speech and Language therapists (N = 2), so did not
have experience of upper limb stroke rehabilitation, or
were not HCP according to our definition (N = 2). Not
all respondents answered all questions; therefore the
numbers of respondents are presented for each question.
Demographic data
Returned questionnaires from 292 HCPs (43% Occupa-
tional therapists (OT), 51% Physiotherapists (PT), 5%
Nurses and 1% Doctors) were analysed. The mean num-
ber of years’ experience of working with stroke was 10.9
(SD = 7.7 min-max 1–45). HCPs respondents (N = 288)
worked across different and sometimes multiple settings:
acute (N = 152), subacute (N = 233), chronic (N =9 6),
and private practice (N = 15). Returned questionnaires
from 123 P&Cs were analysed; 99 (80%) were patients
and 24 (20%) were carers. Thirteen carers completed the
questionnaire on behalf of a patient. Mean time post
stroke (patients) was 8 years (SD 8.4, min-max 0–73).
Access to information about ATs
Most HCPs (92%) had accessed information on ATs
(265/288). Sources were, in order: Continuing Professional
Development courses (176); other non-Continuing Profes-
sional Development courses (171); Internet (152); through
AT companies (88); through their hospital (81); under-
graduate courses (13); and other sources (37) which were
mainly conferences (17) and colleagues (10). Just over half
reported accessing information from more than two
sources (145/288). A smaller proportion of P&C (41%) had
accessed information on ATs (51/123). Sources were, in
order: Internet (29); through their hospital (28); through
AT companies (12); taking part in training courses for
therapists (3); and other, which were mainly stroke groups
(31). 26 respondents had accessed information from more
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three or more sources.
Experience of using of ATs
Both HCP and P&C were asked if and how much they
used ATs and to cite their reasons for not using them
(Table 1). Over half, 59% (170/290) of HCPs had used ATs
in their clinical practice and under half, 44% (108/122) of
P&Cs had used them.
Which ATs are used or prescribed?
154 HCPs and 45 P&Cs provided information on the
ATs they used or prescribed, or in the case of P&C used,
and this is presented in Figure 1a and b respectively. 64
HCPs reported using more than two ATs and five P&Cs
used two types of AT.
Which ATs are used most frequently?
HCPs and P&Cs were asked to report what AT they used
most frequently. The results are demonstrated in Figure 2a
and b respectively. The ATs most frequently used by HCPs
(34%) and P&Cs were FES (47%) and the least used by
both groups were robot therapy and biofeedback.
Respondents’ views on the ATs they had used most
frequently
Respondents who reported using or prescribing a spe-
cific AT frequently (154 HCPs and 45 P&Cs) were asked
the question: ‘Thinking about the AT you use most
often, do you think this device is….’. The responses are
summarised for the HCPs (Table 2) and P&Cs (Table 3).
The number of responders who cited each AT as that
most frequently used is shown and varied among HCPs
from N = 52 for VR to N = 4 for robots. None of the
P&Cs included Robots or Biofeedback as the AT they
used most frequently. Not all responders answered each
question; therefore the number of responders is also
given. Positive responses out of the total number of
responses to each question are presented as a percent-
age. These ‘popular’ ATs were easy to set up, durable,Table 1 HCP and P&C experience of using ATs, and reasons fo




No reason given by 6 respondents
Reasons given by 114 respondents were:
Lack of access (N = 98)
Lack of knowledge (N = 27)
Do not think they work (N = 1)
12/114 cited 2 reasonscomfortable, low risk, evidence-based, good value, and
suitable for home use, and therefore could mainly be
used outside therapy sessions. In general, therapists did
not think that even these popular ATs ‘looked good’ or
‘were fun’ for patients to use. However, they were more
likely to be used at home than in therapy sessions. P&Cs
did not think that ATs were good value for money.
What factors are important in the design of the ideal AT?
The most important factors for the design of an AT were
identified by the focus groups. In the questionnaire
respondents were asked to rank these ‘important factors’
in order of importance by assigning them a score from
one to ten. Their responses are shown in Table 4.
Perceptions about current upper limb rehabilitation and
the use of ATs
It is generally accepted that ATs, if used in upper limb
rehabilitation following stroke, will augment conventional
treatment and this assumption was confirmed by our
respondents. It was therefore also important to gauge
satisfaction with current service provision. Respondents’
perceptions about current upper limb therapy and the use
of ATs are displayed in Figure 3a and b respectively.
Less than 25% of HCPs (Figure 3a) and 20% of P&Cs
(Figure 3b) agreed that people had good arm and hand
therapy in hospital and at home. This perception under-
pins our exploration into ways in which satisfaction with
therapy can be improved and specifically whether ATs
may be useful from the perspective of users.
HCPs and P&Cs were asked the same questions
concerning their beliefs in terms of ATs for upper limb
therapy. They were presented with a series of state-
ments, generated from the focus group data, and asked
whether they strongly agreed, agreed, were neutral, dis-
agreed or strongly disagreed with each statement. The
responses are presented below in a simplified form to
give three categories (Figure 3a and b). In summary, the
views of HCPs and P&Cs were very similar, although
P&Cs reported having less knowledge about ATs, hadr not using ATs




Reasons given by 78 respondents were:
Lack of knowledge (N = 48)
Lack of access (N = 21)
I do not think I need one (N = 9)
A professional told me they were not appropriate (N = 4)
























Type of Assistive Technology used
Figure 1 Responses to the question ‘which of the following ATs





















ATs used most frequently
Figure 2 Responses to the question ‘which AT do you use
(or prescribe) most frequently? (a) HCPs (b) P&Cs.
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thought they had and disagreed less strongly that ATs
might replace therapy. All respondents viewed using ATs
as an efficient use of therapy time and resources; they
saw no reasons why ATs should not be used in the first
4 weeks, and disagreed that ATs should only be used
when conventional therapy had failed. They did not
agree that ATs should only be used with HCPs present,
however they had mixed views on whether unsupervised
use of ATs would lead to poor movement patterns. They
believed that ATs should only be used on HCP recom-
mendation. Both HCPs and P&Cs believed that carer
support was important. Respondents believed there was
a role for ATs in the future, but that they needed more
development.Discussion
This survey provides evidence of HCPs and P&Cs’ views
on the use of ATs in upper limb stroke rehabilitation and
a benchmark from which changing attitudes can be mea-
sured. The results are relevant to all healthcare systems
and particularly those that are free at the point-of-care
such as the UK NHS. ATs will become increasingly im-
portant in the drive to deliver cost-effective improvements
in stroke rehabilitation outcomes and to satisfy, forexample, the UK National Clinical Guidelines for Stroke
[8] that state: “Patients who have some arm movement
should be given every opportunity to practise activities
within their capacity.” Despite the increasing reference to
ATs in healthcare policy, research into effectiveness and
investment in commercial development, no previous sur-
vey has sampled or compared HCPs’ and P&Cs’ views of
ATs. Our survey has generated new information about
factors that influence clinical use of ATs and the oppor-
tunities for and barriers to translation of ATs into clinical
practice. Based on our findings, we discuss how opportun-
ities can be exploited and barriers overcome. We also dis-
cuss the influence our sample may have had on our
findings, the strengths and limitations of the survey and
how it will impact on future work.
Factors that determine clinical use
Strength of evidence for clinical effectiveness and usability
has been cited as an important factor influencing transla-
tion of rehabilitation research into clinical practice [33,34].
The results of our survey generated evidence to support
this: HCPs cited evidence-base as the most important of
ten factors for an ideal technology compared to P&Cs
who ranked it 5th; and who considered both ease of set-up
and comfort as more important. However, despite ranking
evidence-base as the most important factor, many HCPs
Table 2 HCPs responses “yes” to the Question: ‘Thinking about the AT you use most often, do you think this device is…’
‘Thinking about the AT you use most often,
do you think this device is…
VR
N = 34 (%)
Dynamic Splint
N = 23 (%)
Biofeedback
N = 6 (%)
Robots
N = 4 (%)
CIMT
N = 28 (%)
FES
N = 52 (%)
Easy set up (N = 154) 31 (91) 10 (43) 3 (50) 2 (50) 23 (82) 39 (75)
Primarily used in therapy sessions (N = 152) 9 (26) 13 (59) 3 (50) 1 (25) 7 (25) 15 (29)
Suitable for home-use (N = 151) 28 (82) 21 (95) 1 (17) 0 (0) 25 (89) 45 (87)
Looks good (N = 149) 28 (82) 8 (35) 2 (40) 3 (75) 5 (19) 12 (24)
Durable and reliable (N = 150) 29 (85) 17 (74) 4 (67) 4 (100) 20 (70) 45 (86)
Comfortable (N = 154) 32 (94) 18 (78) 5 (83) 3 (75) 20 (70) 40 (77)
Safe (N = 151) 30 (88) 17 (74) 6 (100) 4 (100) 26 (93) 51 (98)
Evidence-based (N = 154) 15 (44) 13 (57) 4 (67) 4 (100) 28 (100) 49 (94)
Good value for money (N = 154) 23 (68) 10 (43) 2 (33) 1 (25) 26 (93) 35 (68)
Fun to use (N = 154) 33 (97) 9 (39) 3 (50) 4 (100) 4 (14) 14 (26)
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FES for example was cited as the most commonly
prescribed AT by both HCPs (96/152 [63%]) and P&Cs,
(16/45 [36%]), yet research evidence is equivocal. The
Evidenced-Based Research in Stroke Rehabilitation, EBRSR)
[35], considers the evidence for FES in improving upper
extremity function in acute stroke to be strong (level 1a),
but the UK National Institute for Clinical Excellence
(NICE) and the National Clinical Guidelines for Stroke
[8], do not consider it strong enough to recommend that
FES is used other than in the context of a clinical trial.
VR, the second most prescribed AT by HCPs (87/152
[57%]), currently has little evidence for its benefit, and is
not recommended by any guidelines, but HCPs scored it
highly on being ‘fun’ and ‘easy’ to use. Robot therapy, the
least cited technology used by either HCPs or P&Cs, by
comparison receives a more positive recommendation
from both the EBRSR and the UK National Guidelines in
terms of evidence for reduction of impairment and im-
provement of shoulder and elbow function which state
that: Robot-assisted movement therapy should only be
used as an adjunct to conventional therapy when the goalTable 3 P&Cs responses “yes” to the Question: ‘Thinking about
‘Thinking about the AT you use most often,
do you think this device is…
VR N = 2 (%) D
Easy set up (N = 45) 1 (50) 6
Primarily used in therapy sessions (N = 44) 2 (100) 6
Suitable for home-use (N = 45) 0 (0) 8
Looks good (N = 37) 0 (0) 1
Durable and reliable (N = 41) 0 (0) 5
Comfortable (N = 42) 2 (100) 6
Safe (N = 44) 1 (50) 8
Based on research evidence (N = 42) 2 (100) 3
Good value for money (N = 43) 0 (0) 4
Fun to use (N = 41) 1 (50) 4is to reduce arm impairment or in the context of a clinical
trial. CIMT, for which there is strong (level 1a) research
evidence and which is recommended by both EBRSR and
the UK Stroke Guidelines was cited as prescribed by HCPs
77/152 [51%] but the AT most frequently prescribed by
only 28/154 (18%) of HCPs. For P&C, CIMT was cited as
the most frequently used AT by 4/45 [<10%] of P&Cs who
responded.
Conflict between clinical use and research evidence
may reflect the absence of definitive research evidence
for any ATs. Other reasons for why some ATs are not
more widely used could be limited applicability – CIMT
is only suitable for people with >20 degrees of wrist ex-
tension and 10 degrees of finger extension, or the un-
willingness of HCPs or P&Cs to use it for practical
reasons, or, in the case of robots and biofeedback, fac-
tors such as cost, unsuitability for home-use, or use
without supervision. In summary therefore, research evi-
dence and evidence-based recommendations currently
have little influence on choice of AT by either P&Cs or
HCPs and other factors, such as usability, may be
regarded by them as more important. Awareness of thethe AT you use most often, do you think this device is…’
ynamic splint N = 11 (%) CIMT N = 4 (%) FES N = 21 (%)
(55) 4 (100) 12 (57)
(55) 1 (25) 11 (52)
(73) 4 (100) 17 (81)
(9) 0 (0) 6 (29)
(45) 2 (50) 13 (62)
(55) 3 (75) 13 (62)
(73) 3 (75) 16 (76)
(27) 2 (50) 15 (71)
(36) 2 (50) 5 (24)
(36) 1 (25) 5 (24)
Table 4 Ranking of factors identified by both HCPs and
P&Cs for design of an ideal AT
Ranking factors for design of an ideal AT HPC rank P&C rank
Good research evidence 1 5
Easy to set up and use 2 1
Low risk of harm 3 3
Comfortable 4 2
Durable and reliable (does not breakdown) 5 4
Value for money 6 8
For use mainly unsupervised at home 7 7
Fun 8 6
For use mainly under supervision of a HCP 9 9
Attractive appearance 10 10
(Responses were weighted so that the factors identified as most important




People with stroke lack confidence to use ATs at home (n=264)
Unsupervised ATs may lead to poor movement (n=263)
ATs should only be used on HCP recommendation (n=258)
ATs should only be used when HCP present (n=263)
ATs only used when therapy failed (n=259)
No reason why ATs not used in first 4 weeks (n=260)
Do not know much about ATs (n=262)
Using ATs is efficient use of therapy time (n=260)
ATs may be used to replace therapy (n=266)
Difficult to access training/advice (n=263)
Carer support important for using ATs (n=266)
ATs useful in the future, needs development (n=263)
Good arm and hand therapy at home (n=266)
Good arm and hand therapy in hospital (n=264)
Strongly disagree/disagree N
Figure 3 Perceptions about current upper limb therapy and the use o
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http://www.biomedcentral.com/1472-6963/14/124evidence may also be a factor. All HCPs who used CIMT
and robots and most (94%) who used FES thought that
those ATs were evidence-based; yet only CIMT is rec-
ommended by both the UK and EBRSR guidelines.
These findings highlight the need to improve the
evidence-base for ATs, particularly those that are currently
being used and that satisfy the requirements of the res-
pondents such as: ease of set up; fun to use; safe; comfort-
able and durable.
Mismatch between strength of research evidence
and clinical use has been reported previously [34] and
the survey identified examples of technologies that are
becoming widely used in clinical practice for which
there has been strong commercial drive and invest-
ment. For example, the Saeboflex (www.saebo.com) is20% 40% 60% 80% 100%
Percentage
eutral Strongly agree/agree
f ATs (a) HCPs (b) P&Cs.
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who manufacture upper and lower limb FES devices re-
port increasing sales and reimbursement, and O2 have
launched a project to make the ‘Wii fit’ available to
stroke patients as part of their Global e-health strategy
(www.oz.com). None of these devices has undergone
large-scale clinical trials.
Conflict between key sources of information regarding
effectiveness suggests that other factors are important in
determining clinical use of ATs. Inevitably, in the ab-
sence of clear research evidence and guidance, HCPs’
decision-making is influenced by anecdotal evidence and
their own experience. These may incorporate a complex
integration of factors including observed clinical effect-
iveness, what they rate as important and the views of the
patient and sometimes the carer. Our findings suggest
that therapists take a pragmatic view when it comes to
using ATs. They prioritise evidence, but also acknow-
ledge that usability is crucial to avoid AT abandonment.
One reason for this, that has been suggested, is lack of
consideration of user opinion in design and selection
of ATs [36].
Cost effectiveness is a key factor in the adoption of any
new treatment into clinical practice. The cost-effectiveness
of using robots for upper limb rehabilitation, for example,
has been reported in a single randomised controlled trial
that also demonstrated modest clinical benefits compared
with usual care at 36 weeks [37], but further empirical re-
search using economic analysis is required to demonstrate
consistent results. In the UK a 3-arm RCT of robot ther-
apy with an expected sample size of N = 720 is currently
being undertaken (http://www.nets.nihr.ac.uk/projects/
hta/112605). The trial will generate the required evi-
dence, however, cost-effectiveness in the use of expensive
technologies is heavily dependent on how much devices
are used and the proportion of patients who benefit. Our
survey has shown that cost-effectiveness does not gua-
rantee that new treatments, especially those that rely on a
change in practice (such as ATs), will automatically be
adopted [8].
Opportunities for ATs in clinical practice
Changes in care pathways following stroke and the drive
for more efficient use of rehabilitation services provide
an opportunity to develop ATs, especially those that can
be used outside hospital and without supervision. The
results of the survey provide clear indicators for what is
needed to enable this to happen: i.e. more usable tech-
nologies and better clinical evidence. Our findings provide
indications for the design of new ATs. The top five factors
considered by both HCPs and P&Cs as critical for accept-
ance were: evidence-based, ease of set-up, safety, comfort
and durability. They also need to be generalizable to many
patients at different stages of recovery and in differentsettings – factors that were shown to be met by some ATs.
Knowledge of these factors and response to them is
critical in the design of future ATs.
Barriers to clinical use
The survey has identified barriers to clinical use of ATs,
but understanding them is fundamental to overcoming
them. Much can be learnt from the wider field. For
example, Reynaud (2008), proposed different models of
acceptance (an attitude) and adoption (a process) of
technologies from the fields of information systems and
sociology [38]. These models can be applied to any tech-
nology type, but can also be specialised to individual
technologies. Acceptance models, such as the Technology
Acceptance Model (TAM) [39,40], suggests that when
users are presented with a new technology a number of
factors influence their decision about how and when they
will use it, including “perceived usefulness” (the extent to
which a person believes that using a particular system
would enhance their performance) and “perceived ease-
of-use” (the extent to which a person believes that using a
particular system would be free from effort). This model,
which has been updated several times [41-43], corre-
sponds with the findings from the survey presented in
Table 4 for the high priority given by both HCPs and
P&Cs to the ease of set up and use for an ideal technology.
Technology adoption processes reported included those
developed by Rogers [44] and Silverstone and Haddon
[45]. In the former, the model aims to provide a framework
for understanding how technology innovations change,
and are changed, by their social contexts. In the latter, the
model focuses mostly on the individual’s decision to buy
or not to buy. At a systems level the Normalization
Process model was developed to assist both service pro-
viders and research constituencies in understanding how
health care interventions, technologies, and practices are
implemented, embedded, and integrated in everyday life
[46]. These models could be applied more widely within
the AT field to assess key barriers to the translation of
individual technologies and should be integrated into
clinical effectiveness trials. Based on the survey’s findings,
barriers reported by HPC and P&C were a lack of know-
ledge and access to ATs the following are recommenda-
tions to address these.
Knowledge-transfer and changes in service provision -
key opportunities to translate ATs into clinical practice,
are currently not exploited and therefore remain barriers.
For example 41% of HCPs and 64% of P&Cs had not used
ATs. When asked why not, 98/114 (86%) HCPs cited lack
of access and 27/114 (24%), lack of knowledge. Among
P&C respondents 48/78 (62%) knew nothing about them
and 21/78 (27%) said they could not get one on the NHS.
Similar responses were expressed in the ‘views’ section of
the questionnaire, for example only 10% of P&Cs and 21%
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that it was ‘difficult to access training or advice’. Training
was also identified as an important area for further devel-
opment and could be used to raise HCPs awareness of
research evidence.
Until ATs become a core element of therapist’s training
they are unlikely to be used in routine clinical practice,
but without evidence for their effectiveness, inclusion is
hard to justify, despite the fact that many approaches to
stroke rehabilitation currently taught are not evidence-
based. A more pragmatic approach would be to include
opportunities for learning about ATs (as well as training in
using them) at post-qualifying level. Collaboration bet-
ween universities, healthcare providers and the commer-
cial sector may be an effective way of providing this. The
wider study (of which this survey was part) began with an
interactive exhibition of ATs that brought together com-
mercial companies demonstrating a wide range of tech-
nologies, and patients, carers, researchers and clinicians.
In doing so we increased clinicians’ awareness, knowledge
and understanding of ATs and established a communica-
tion network between clinicians, researchers and the
commercial sector that has been influential in the forma-
tion of the International Industrial Society in Advanced
Rehabilitation Technologies (IISART). Awareness may be
increased by similar exhibitions, run by trade organi-
sations, in collaboration with universities providing
healthcare courses nationally, or with regional or national
specialist interest groups for HCPs. Keeping up-to-date
with new information, given the time constraints in clin-
ical practice, has been recognised as a barrier to achieving
evidence-based stroke rehabilitation [47]. Professional
bodies can play a role in removing barriers by providing
independent advice, based on new evidence, and employ-
ing a variety of accessible Internet-based methods such as
webinars and podcasts.
Access to ATs is posited as a key factor that influences
whether therapists have used or prescribed them. Cur-
rently, access to ATs in the UK is through commis-
sioners of stroke services, who require a business case to
justify their provision that identifies the cost benefits of
using ATs, both in the short and long term. This would
ideally include service level benefits: proven implemen-
tation in other regions, a description of need, number of
people suitable for treatment, level of resource required
(e.g. reduced costs through fewer repeat visits to the
service; reduced level of social care and reusability of
equipment). It would also include plans for auditing use
such as number of suitable patients and duration of use.
In addition, commissioners need estimates of benefits
for patients, such as quality of life outcomes and in-
creased social activity. Increased collaboration between
HCPs and manufacturers is an additional way of providing
better access to ATs, through for example, training andATs ‘on-loan’, enabling HCPs to be more knowledgeable
and experienced in using them.
The survey identified a conflict between research evi-
dence and clinical use of ATs, and thus a failure in transla-
tion of research into clinical practice. Translation may be
more efficient if research studies are pragmatic – testing
ATs in the environment in which they will be used clinic-
ally and incorporating robust examination of user’s views
and the burden that the AT makes on users. Furthermore,
involving end users, both HCPs and P&Cs, into the design
of clinical trials, may facilitate translation.
Characteristics of respondents that may have influenced
the views expressed
P&Cs and HCPs had similar views about current upper
limb post-stroke rehabilitation (although it is important
to note that because P&Cs’ mean time post-stroke was
8 years their personal experience may not reflect current
practice). Views on the use of ATs were also similar
between groups, although P&Cs were more confident
about using ATs at home than HCPs were about patients
and carers using them. The views of P&Cs and HCPs
regarding ATs are also remarkably similar, increasing
the validity and usefulness of the findings for providers of
stroke rehabilitation services, researchers and developers
of ATs.
Strengths and limitations of the study
The study has several strengths. It is based on a nation-
wide survey of a large number of HCPs (n = 292) who
work with stroke in a range of settings and 123 P&C
who have experienced a stroke. The questions were
developed using data generated by focus groups and
subsequently pre and pilot tested to ensure relevance,
comprehensiveness and to minimise bias. However there
were limitations. There is a selection bias in the way the
questionnaires were designed and potentially responded
to. The methodology was designed to recruit a sample of
the population of P&Cs and HCPs working in stroke
rehabilitation. However, it is likely that, being a self-
selected sample, the results are biased towards the views
of people interested in ATs. Factors that will have con-
tributed to this are that some respondents would have
attended the exhibition. Whilst the questionnaire data
were from a national sample, the majority of whom had
not attended the exhibition, and as such were likely to
be more representative of national views and experi-
ences, people may have been more likely to look for and
complete the questionnaire if they had an interest in
ATs. In that respect knowledge and use of ATs reported
here might be greater than in the population as a whole
and the views expressed may be more positive. Addition-
ally, the response rate cannot be specified for the online
version of the questionnaire, and the fact the data were
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whether the data are directly comparable. The number
of individuals involved is uncertain, for instance we can-
not guarantee that individuals have not completed more
than one questionnaire, and the representativeness of
the responses is uncertain. Motivation to respond to the
questionnaire may have differed across the different
professional groups, leading to biased estimates of the
popularity of some interventions. Another limitation of
the study is that it was based on self-report: HCPs reports
of their practice may not reflect actual practices. Some
patients had suffered their first stroke many years before
completing the questionnaire; their experiences may
therefore not be up-to-date. Moreover, a social desirability
bias (adapting responses to meet what people believe they
should be thinking) cannot be ruled out especially when
considering attitudes and opinions. Test re-test reliability
and internal consistency were not tested, which along with
cognitive interviewing processes would have strengthened
the data.
Future work
This work has been conducted in parallel with surveys
of stroke services to determine current AT rehabilitation
methods and systematic literature reviews to provide
both narrative descriptions and quantitative comparisons
of each AT for upper limb function. This information
will be used to determine which combination of ATs has
the greatest probability of significantly improving upper
limb rehabilitation following stroke, is cost effective and
acceptable for use by patients and in health services.
Results from this work have directly informed the design
of a clinical trial which will be used to propose a new
service delivery model, as well as provide an operational
framework for future studies. Engagement with all stake-
holders has been embedded through the whole programme
of work.
Further work could explore the results of the current
survey with, for example, qualitative interviews, with a
purposive sample of respondents. Longitudinal studies
would help to determine how quickly attitudes to arm
and hand rehabilitation, and use of ATs in practice are
changing.
Conclusion
Research evidence was seen as critical to clinical use, yet
our findings suggest that key barriers to the translation
of ATs into clinical practice are usability, knowledge,
education, awareness and access to ATs. Use of ATs and
perceptions varied between professional groups as well
as with years’ experience, but overall responses from
HCPs & P&Cs were remarkably similar. Opportunities
exist to overcome barriers, through better communication
between manufacturers, educators, HCPs and P&Cs. Withan understanding of these factors, AT designers, manufac-
turers and marketing experts can create ATs for HCP and
P&C preferences and target marketing information more
effectively. Based on our findings, improvements in AT
design, pragmatic clinical evaluation, better knowledge
and awareness and improvement in provision of services
will enable useful ATs to be used in clinical practice and
therefore contribute to better and cost-effective upper
limb stroke rehabilitation.
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